Horizon Therapeutics To Buyback Up To $500 Mln Of Ordinary Shares
(RTTNews) - Biotechnology company Horizon Therapeutics plc (HZNP) today announced that its Board of Directors authorized the repurchase of up to $500 million of the Company's ordinary shares.
Under the program, the Company may repurchase ordinary shares from time to time on the open market or through privately negotiated transactions or structured repurchase transactions.
As of June 30, 2022, the Company had cash and cash equivalents of $1.89 billion. The Company expects to fund the repurchase of its ordinary shares under the program with existing cash and cash equivalents.
baca selengkapnya
Amgen, Horizon Therapeutics Reach Settlement On FTC Lawsuit; Seeks To Close Acquisition In Q4
Amgen (AMGN) and Horizon Therapeutics plc (HZNP) announced Friday the entry into a consent order agreement with the Federal Trade Commission (FTC) that resolves the pending FTC administrative lawsuit. This clears the path to take the final steps to close Amgen's $27.8 billion acquisition of Horizon.
RTTNews
|
1156 hari yang lalu
Horizon Says UPLIZNA Approved By Brazilian Health Regulatory Agency As Monotherapy For NMOSD
Biotechnology company Horizon Therapeutics plc (HZNP) announced Tuesday that the Brazilian Health Regulatory Agency (ANVISA) has approved UPLIZNA as a monotherapy for the treatment of adult patients with NMOSD who are AQP4-IgG+.
RTTNews
|
1411 hari yang lalu
Xeris Biopharma Inks Research Collaboration With Horizon Therapeutics To Develop Teprotumumab
Biopharmaceutical company Xeris Biopharma Holdings, Inc. (XERS) announced Wednesday that it has entered into a research collaboration and option agreement with Horizon Therapeutics plc (HZNP).
RTTNews
|
1438 hari yang lalu
Horizon Says Phase 2 Trial Of Dazodalibep To Treat Sjögren's Syndrome Met Primary Endpoint
Horizon Therapeutics plc (HZNP) announced Monday that its Phase 2 trial evaluating dazodalibep for the treatment of Sjögren's syndrome met the primary endpoint in patients with moderate-to-high systemic disease activity. Sjögren's syndrome is a disease with no FDA-approved treatments available.
RTTNews
|
1510 hari yang lalu
U.S. Dollar Ticks Lower As Investors Monitor Developments In Middle East
The U.S. Dollar value posted incremental losses on Friday as markets focused on the U.S. call to Iran for discussions to avert a planned intense attack by the U.S. on Iran after November mid-term elections. Iran has not responded until now.
RTTNews
|
1 hari yang lalu
TSX Drops Nearly 2.5%; Materials, Tech Stocks Down Sharply
Canadian stocks are down sharply on Friday amid renewed fears about inflation and interest rates following oil prices climbing higher amid supply concerns after a tanker attack in the Strait of Hormuz.
RTTNews
|
1 hari yang lalu
Swiss Market Ends Modestly Higher
The Switzerland market's benchmark SMI ended modestly higher on Friday after holding firm throughout the trading session, outperforming most of its peers in Europe.
RTTNews
|
1 hari yang lalu
Major European Markets End Mixed As Investors React To Earnings, Economic Data
The major European markets closed mixed on Friday even as most of the other markets across the continent ended notably lower, as investors reacted to a slew of corporate earnings announcements and the latest batch of regional economic data.
Higher oil prices and weakness in the tech sector due to renewed uncertainty about returns on AI-related investments hurt sentiment.
RTTNews
|
1 hari yang lalu
